Stock Taper
SCREENER COMPARE ANY 2 STOCKS
AGIO
AGIOS PHARMACEUTICALS, INC.
NASDAQ
$33.32
▼ DOWN 2.80% (-0.96)

KEY STATISTICS

Market Cap$1.99 B
52w High$46.00
52w Low$22.24
Dividend Yield—
Frequency—
P/E-4.60
Volume519.74K
Shares Out.59.70M

COMPANY

LEADERSHIP

Brian Goff
CHIEF EXECUTIVE
Brian Goff

COMPENSATION 2026

Salary$846,864
Stock Awards$1,291,680
Incentive Plan Pay$592,804
All Other Comp.$11,789
Total$5,370,389

ABOUT

SECTOR
Healthcare
WENT PUBLIC
July 24, 2013
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
540

PRICE TARGET

Target High$55.00
Target Low$32.00
Target Median$41.00
Target Consensus$42.67

UPCOMING EARNINGS

DateOct 29, 2026
DayThursday
Rev. Est.$53.80M
OCT
29
THU

PRICE

$33.32 ▼ DOWN 2.80% (−$0.96)
$33.40$33.60$33.80$34.009:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM33.32

About Agios Pharmaceuticals, Inc.

https://www.agios.com ↗

Agios Pharmaceuticals, founded in 2007 and based in Cambridge, MA, develops medicines targeting cellular metabolism, including PYRUKYND for hemolytic anemias and AG-946 in Phase I trials.

INDUSTRY

Biotechnology

A PRODUCT AGIOS PHARMACEUTICALS, INC. IS KNOWN FOR

AQVESME™ (mitapivat)
AQVESME™ (mitapivat)

AQVESME™ is the first approved oral therapy for anemia in adults with alpha- or beta-thalassemia, launched in the U.S. in January 2026, reflecting Agios' focus on innovative treatments for rare hematological diseases.

COMPETITORS

COMPETITOR
BMY COMPARE
CRSP COMPARE
NVO COMPARE
VRTX COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Product$12.88M $19.97M ▲$20.75M ▲$44.74M ▲

Revenue by Geography

MapREGIONQ1-2026Q2-2026
NonUS$1.9M $3.83M ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
170
LISTED HERE
26
RANKED BY POSITION SIZE
XBI
0.61% · 2.1M
VTI
0.00% · 1.9M
IWM
0.06% · 1.5M
SCHA
0.04% · 281.3K
DFMC
0.11% · 245.4K
FYC
0.35% · 150.7K
AVSC
0.13% · 119.1K
PRFZ
0.13% · 113.7K
LABU
0.42% · 77.5K
SBIO
1.01% · 73.3K
XRSG.L
0.06% · 55.5K
HAPS
0.96% · 50.0K
BBP
1.43% · 49.7K
FESM
0.02% · 36.0K
VALT
0.45% · 29.2K
RSSL
0.06% · 28.2K
BIGT.L
2.81% · 19.9K
ISMD
0.18% · 18.5K
ETHO
0.28% · 16.5K
BBSC
0.07% · 16.0K
WBIO.L
1.24% · 12.3K
GSSC
0.03% · 10.8K
TILT
0.01% · 4.6K
RFLR
0.12% · 3.3K
URTY
0.02% · 2.4K
VETS
0.14% · 1.6K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
80.56%
HOLDERS
388
TOP 12 OF 388 · RANKED BY POSITION SIZE
Blackrock, Inc.
6.5M sh · $239.58M
Farallon Capital Management LLC
5.9M sh · $219.59M
Vanguard Group Inc
5.6M sh · $224.98M
Blackrock Inc.
4.9M sh · $209.52M
Bellevue Group AG
3.7M sh · $149.11M
State Street Corp
3.5M sh · $131.14M
Lynx1 Capital Management LP
3.4M sh · $126.51M
D. E. Shaw & Co., Inc.
3.1M sh · $115.3M
Armistice Capital, LLC
3.0M sh · $82.64M
Bb Biotech AG
3.0M sh · $200.84M
Erste Asset Management Gmbh
2.8M sh · $76.34M
Paradigm Biocapital Advisors LP
2.7M sh · $107.32M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book3
Overall Score2

TRADES BY CONGRESS

HOUSE TRADES
Gilbert Cisneros
Gilbert Cisneros
Purchase
2026-03-03
 Josh Gottheimer
Josh Gottheimer
Purchase
2024-01-24

INSIDER TRADES

★
OFFICER: CHIEF MEDICAL OFFICER
Gheuens Sarah
Sale · 30.0K shares
2026-08-04
★
DIRECTOR
Backstrom Jay T.
Sale · 1.4K shares
2026-07-08
★
DIRECTOR
Backstrom Jay T.
Purchase · 1.4K shares
2026-07-08
★
OFFICER: CHIEF MEDICAL OFFICER
Gheuens Sarah
Sale · 4.0K shares
2026-07-01

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 4
NEUTRAL 2
SECTOR PERFORM 1
OUTPERFORM 1
8 GRADES IN THE LAST 12 MONTHS
JP Morgan NEUTRAL Citigroup BUY Truist Securities BUY HC Wainwright & Co. BUY RBC Capital SECTOR PERFORM B of A Securities BUY Goldman Sachs NEUTRAL Leerink Partners OUTPERFORM

SECTORS PEERS

PEERPRICE
IBRX$8.05COMPARE
LQDA$67.69COMPARE
COGT$34.67COMPARE
DNLI$24.00COMPARE
RCUS$29.21COMPARE
BEAM$29.32COMPARE
SRPT$20.86COMPARE
RXRX$3.34COMPARE